Yukako Yokota came to venture investing after working as a researcher at Biogen and earning a Ph.D. in neuroscience, publishing in journals like Neuron, Nature Neuroscience, and PNAS, and she has stayed close to hands-on healthcare work, including serving as an outside board director for the pathology AI company Medmain. Having grown up in the Netherlands and studied in Japan and the U.S., she works comfortably in both Japanese and English, and her arrival at One Capital was seen as a key reason the firm deepened its focus on healthcare investing.
About their Fund
One Capital is a Japan-focused enterprise software VC, started by Shinji Asada after he left Salesforce Ventures wanting to be a more hands-on partner to founders, and it raised the largest first-time VC fund in Japan's history at $170M while focusing on Japan's low SaaS penetration and opportunity to replace legacy software; it looks for founders who are alumni of major US tech firms or early employees at successful public Japanese tech companies, and it recently added healthcare expertise through former McKinsey partner Yukako Yokota. The firm sets itself apart by building its own SaaS tools (like Projection-ai) and using 100+ SaaS products internally to evaluate startups as real users, by using its fund to help large Japanese companies digitize over ten-year relationships, by publishing widely cited Japan SaaS Insights research, and by drawing about 20% of its second fund from international investors in the US and Singapore.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































